148 related articles for article (PubMed ID: 18925841)
21. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
22. Sarcoidosis in a clinically unaffected joint demonstrated by somatostatin receptor scintigraphy.
Kroot EJ; Dolhain RJ; van Hagen PM; Kwekkeboom DJ
Clin Nucl Med; 2006 Aug; 31(8):501-3. PubMed ID: 16855445
[No Abstract] [Full Text] [Related]
23. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Chiti A; Spinelli A; Bombardieri E
Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
[No Abstract] [Full Text] [Related]
24. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
25. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
26. [Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide].
Dabasi G; Hauser P; Kertész GP; Balázs G; Karádi Z; Constantin T; Bognár L; Klekner A; Schuler D; Garami M
Magy Onkol; 2007; 51(3):229-34. PubMed ID: 17922063
[TBL] [Abstract][Full Text] [Related]
27. Rare Orbital Metastasis Originating From a Neuroendocrine Tumor.
Beam AS; Moore KG; Stephens CP; West SJ; Barfield J; Dean C; Eldridge T; Green J; Vijayakumar V
Radiol Technol; 2019 Nov; 91(2):112-119. PubMed ID: 31685587
[TBL] [Abstract][Full Text] [Related]
28. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
29. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.
Krenning EP; Kwekkeboom DJ; de Jong M; Visser TJ; Reubi JC; Bakker WH; Kooij PP; Lamberts SW
Semin Oncol; 1994 Oct; 21(5 Suppl 13):6-14. PubMed ID: 7992084
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin and the concept of peptide receptor scintigraphy in oncology.
Lamberts SW; Reubi JC; Krenning EP
Semin Oncol; 1994 Oct; 21(5 Suppl 13):1-5. PubMed ID: 7992074
[No Abstract] [Full Text] [Related]
32. Indium 111 octreotide scintigraphy in angiofibroma.
Guneri EA; Degirmenci B; Durak H; Ikiz AO; Derebek E; Sutay S
Otolaryngol Head Neck Surg; 1998 Jan; 118(1):137-9. PubMed ID: 9450844
[No Abstract] [Full Text] [Related]
33. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
[No Abstract] [Full Text] [Related]
35. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
36. An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis.
Kurtaran A; Ofluoglu S; Traub T; Tribl B; Speiser P; Grabenwöger F; Schima W; Dudczak R; Virgolini I
Am J Gastroenterol; 2000 May; 95(5):1367-8. PubMed ID: 10811361
[No Abstract] [Full Text] [Related]
37. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
38. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
39. Influence of isotope dose on somatostatin receptor imaging: when less is better.
Schirmer TP; O'Dorisio TM; Olsen JO; Hinkle GH; O'Dorisio MS; Schirmer WJ
Semin Oncol; 1994 Oct; 21(5 Suppl 13):51-5. PubMed ID: 7992082
[No Abstract] [Full Text] [Related]
40. Bilateral orbital metastases from a neuroendocrine tumor.
Sivagnanavel V; Riordan-Eva P; Jarosz J; Portmann B; Buxton-Thomas M
J Neuroophthalmol; 2004 Sep; 24(3):240-2. PubMed ID: 15348994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
